# US 2024/0404673 A1 · Dosing of incretin pathway drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0404673 A1
- Document ID: US20240404673A1
- Status: Published application
- Kind: A1
- Application number: 18/734,284
- Filed: 2024-06-05
- Published: 2024-12-05
- Earliest claimed: 2023-06-05
- Assignees: Closed Loop Medicine Ltd.
- Applicants: Closed Loop Medicine Ltd.
- Inventors: Paul GOLDSMITH; David Bruce CAMPBELL; Michael CATT; Tom GODEC; Joe COGHLIN
- Web page: https://patentgrep.com/patent/US20240404673A1

## CPC

- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 20/17: delivered via infusion or injection
- A61K 38/26: Glucagons
- G16H 20/60: relating to nutrition control, e.g. diets
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/50: for simulation or modelling of medical disorders
- G16H 70/40: relating to drugs, e.g. their side effects or intended usage
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A computer implemented method for determining a dosage of semaglutide for administering to a patient for the treatment of obesity includes receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data with a dosage calculator to determine the dosage of semaglutide for administering to the patient; and administering the dosage.

## Claims

### Claim 1

A method for administering a dosage of semaglutide to a patient for the treatment of obesity, the method comprising:
receiving patient data relating to a patient, wherein the patient data includes patient weight data;
processing the patient data including the patient weight data with a dosage calculator to determine the dosage of semaglutide for administering to the patient; and
administering the determined dosage of semaglutide to the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dosage calculator is derived from a pharmacokinetic, PK, model.

### Claim 3 (depends on 2)

The method of claim 2, wherein the PK model comprises a personalised energy intake-total daily energy expenditure model.

### Claim 4 (depends on 1)

The method of claim 1 comprising processing the patient weight data with the dosage calculator to determine an initial dosage for administering to the patient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the patient weight data includes an initial weight and a target weight and the method comprises processing the initial weight and the target weight with the dosage calculator to determine the initial dosage.

### Claim 6 (depends on 5)

The method of claim 5, wherein processing the initial weight and the target weight with the dosage calculator to determine the dosage comprises:
setting a target drug concentration based on the initial weight and the target weight; and
determining the initial dosage based on the target drug concentration and the initial weight.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method comprises:
setting a target drug concentration comprising a target plasma level from 50 nmol/L to 100 nmol/L; and
determining an initial dosage based on the target drug concentration and the initial weight.

### Claim 8 (depends on 6)

The method of claim 6, wherein the patient data further comprises one or more of: a patient age; a patient ethnicity; a patient gender; a patient diabetes history; a kidney function metric; a treatment purpose; a dosage route; a pharmacogenomic profile and a patient medication list, and wherein the method comprises determining the initial dosage based on the target drug concentration and the patient data.

### Claim 9 (depends on 1)

The method of claim 1, wherein the patient data further comprises a patient side effect tolerance and the method comprises processing the patient side effect tolerance with the dosage calculator to determine an initial dosage.

### Claim 10 (depends on 9)

The method of claim 9, wherein the method comprises:
processing the patient side effect tolerance and the patient data with the dosage calculator to obtain a target drug concentration that satisfies the patient side effect tolerance; and
processing the target drug concentration with the dosage calculator to determine the initial dosage.

### Claim 11 (depends on 10)

The method of claim 10, wherein the dosage calculator comprises a side-effect calculator derived from a side effect model comprising a discrete-time Markov side effect model or an Emax exposure response side effect model.

### Claim 12 (depends on 1)

The method of claim 1 further comprising:
receiving updated patient data including updated patient weight data; and
processing the updated patient data with the dosage calculator to determine an updated dosage; and
administering the updated dosage.

### Claim 13 (depends on 12)

The method of claim 12, wherein processing the updated patient data with the dosage calculator to determine an updated dosage comprises one or more of:
increasing the dosage if the updated weight data indicates a weight loss is less than a lower weight loss threshold; and
reducing the dosage if the updated weight data indicates a weight loss greater than an upper weight loss threshold.

### Claim 14 (depends on 12)

The method of claim 12, wherein the updated patient data includes patient satiety data and processing the updated patient data with the dosage calculator to determine an updated dosage comprises one or more of:
reducing the dosage if the patient satiety data indicates a patient satiety greater than a first patient satiety threshold; and
increasing the dosage if the patient satiety data indicates a patient satiety less than a second patient satiety threshold.

### Claim 15 (depends on 12)

The method of claim 12, wherein the updated patient data includes reported side effect data and wherein processing the updated patient data with the dosage calculator to determine an updated dosage comprises reducing the dosage if the reported side effect data satisfies one or more side effect severity thresholds.

### Claim 16 (depends on 12)

The method of claim 12, wherein the updated patient data includes a patient metabolism metric from a physiological test result and the method comprises updating the dosage calculator based on the patient metabolism metric.

### Claim 17 (depends on 1)

The method of claim 1, wherein the dosage calculator comprises a machine learning algorithm trained using a PK model.

### Claim 18 (depends on 1)

The method of claim 1, wherein processing the patient data with the dosage calculator to determine the dosage of semaglutide for administering to the patient comprises:
processing the patient data with the dosage calculator to determine an ideal dosage regime; and
selecting the dosage for administering to the patient from a selection of available dosage regimes based on the ideal dosage regime.

### Claim 19 (depends on 18)

The method of claim 18, wherein the selection of available dosage regimes comprise dosage amounts comprising one or more of: 0.25, 0.5, 1.0, 1.7 and 2.4 mg of subcutaneous semaglutide for administration once weekly.

### Claim 20 (depends on 18)

The method of claim 18, wherein the selection of available dosage regimes comprise:
dosage amounts of subcutaneous semaglutide comprising any integer multiple of 0.05 mg from 0.05 mg up to 10.00 mg; or
dosage amounts of oral semaglutide comprising any integer multiple of 0.25 mg from 0.25 mg up to 30.00 mg.

### Claim 21 (depends on 1)

The method of claim 1, further comprising:
setting a calorie intake regimen based on the patient data; and
indicating the calorie intake regimen.

### Claim 22 (depends on 21)

The method of claim 21, wherein the dosage comprises an initial dosage and the method comprises:
setting the calorie intake regimen based on an initial weight and a target weight of the patient weight data; or
determining an expected energy intake trajectory based on the initial dosage; and
setting the calorie intake regimen based on the expected energy intake trajectory.

### Claim 23

A method for treating a patient for obesity, the method comprising:
receiving patient data relating to the patient, wherein the patient data includes patient weight data;
processing the patient data including the patient weight data with a dosage calculator to determine an effective dosage of semaglutide to administer to the patient; and
administering the determined effective dosage of semaglutide to the patient to treat the patient for obesity.
